Do we really understand pimecrolimus?
Marc
M
Vorpahl
Aloke V
AV
Finn
Masataka
M
Nakano
Renu
R
Virmani
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000209:etiology* / Q000473:pathology; D023921:Coronary Stenosis / Q000473:pathology / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D006965:Hyperplasia; D011108:Polymers; D011474:Prosthesis Design; D018570:Risk Assessment; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D014992:Xylenes
D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible; D011108:Polymers; D014992:Xylenes; C011055:parylene; C117268:pimecrolimus; D016559:Tacrolimus